Evidence map›Paper›PMID 30946934›Full record

ArticleHuman pathology2019

A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma.

Sounak Gupta, Carlos P Sosa, Farhad Kosari, Andrew Folpe, Kaustubh N Bhinge, Lin Yang, Alireza Agahi, Sarah H Johnson, Igor Frank, Stephen A Boorjian and 7 more

Open access · greenAbstract readComparative Study
In one paragraph

Article in Human pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Sounak GuptaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905. Electronic address: guptas1@mskcc.org.
Carlos P SosaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905. Electronic address: Sosa.Carlos@mayo.edu.
Farhad KosariDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905. Electronic address: Kosari.Farhad@mayo.edu.
Andrew FolpeDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905. Electronic address: folpe.andrew@mayo.edu.
Kaustubh N BhingeDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905. Electronic address: Bhinge.Kaustubh@mayo.edu.
Lin YangDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905. Electronic address: Yang.Lin@mayo.edu.
Alireza AgahiDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905. Electronic address: Agahi.Alireza@mayo.edu.
Sarah H JohnsonCenter for Individualized Medicine, Mayo Clinic, Rochester, MN 55905. Electronic address: Johnson.Sarah14@mayo.edu.
Igor FrankDepartment of Urology, Mayo Clinic, Rochester, MN 55905. Electronic address: Frank.Igor@mayo.edu.
Stephen A BoorjianDepartment of Urology, Mayo Clinic, Rochester, MN 55905. Electronic address: Boorjian.Stephen@mayo.edu.
Donna E HanselDepartment of Pathology, University of California at San Diego, CA 92093. Electronic address: dhansel@ucsd.edu.
Hikmat A Al-AhmadieDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065. Electronic address: alahmadh@mskcc.org.
Victor E ReuterDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065. Electronic address: reuterv@mskcc.org.
George VasmatzisDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905. Electronic address: vasm@mayo.edu.
Rafael E JimenezDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905. Electronic address: Jimenez.Rafael@mayo.edu.
Loren Herrera-HernandezDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905. Electronic address: HerreraHernandez.Loren@mayo.edu.
John C ChevilleDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905. Electronic address: Cheville.John@mayo.edu.
Mayo Clinic in Arizona · USMemorial Sloan Kettering Cancer Center · USMayo Clinic · USUniversity of California, San Diego · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Some rhabdomyosarcomas and sarcomatoid carcinomas with heterologous rhabdomyosarcomatous elements resemble high-grade neuroendocrine carcinoma, creating a diagnostic difficulty. The purpose of this study was to characterize the overlap of adult genitourinary rhabdomyosarcomas, excluding those occurring at paratesticular sites, with high-grade neuroendocrine carcinoma and identify features helpful in their separation. Seventeen cases of rhabdomyosarcoma (11 from the urinary bladder and 3 each from kidney and prostate) were compared to 10 cases of high-grade neuroendocrine carcinoma from the urinary bladder. These tumors were analyzed by immunohistochemistry for desmin, MyoD1, myogenin, chromogranin, synaptophysin, CD56, TTF1, and ASCL1, and RNA sequencing was performed on 4 cases of bladder rhabdomyosarcoma (2 rhabdomyosarcomas and 2 sarcomatoid-rhabdomyosarcoma) and 10 cases of bladder high-grade neuroendocrine carcinoma. This was compared to public data from 414 typical urothelial carcinomas from The Cancer Genome Atlas dataset. Morphologic and immunophenotypic overlap with high-grade neuroendocrine carcinoma was seen in half of the bladder tumors, which included 4 rhabdomyosarcomas and 2 sarcomatoid rhabdomyosarcomas. RNA sequencing confirmed expression of neuroendocrine markers in these cases (2 rhabdomyosarcomas and 2 sarcomatoid rhabdomyosarcomas). Differential neuroendocrine differentiation was highlighted by ASCL1 protein expression only in high-grade neuroendocrine carcinoma. Moreover, both a pure alveolar rhabdomyosarcoma and sarcomatoid rhabdomyosarcoma of the urinary bladder demonstrated a fusion involving PPP1R12A. In summary, adult rhabdomyosarcomas of the urinary bladder are molecularly distinct from high-grade neuroendocrine carcinomas based on specific patterns of expression of myogenic and epithelial to mesenchymal transition-related transcription factors as well as the presence of a novel PPP1R12A fusion which is seen in a subset of cases.

Indexed as

AdultAgedAged, 80 and overBasic Helix-Loop-Helix ProteinsBiomarkers, TumorCarcinoma, NeuroendocrineDiagnosis, DifferentialFemaleGene ExpressionGene FusionHumansKidney NeoplasmsMaleMiddle AgedMuscle DevelopmentMyosin-Light-Chain PhosphataseASCL1 protein, humanBasic Helix-Loop-Helix ProteinsBiomarkers, TumorMyosin-Light-Chain PhosphatasePPP1R12A protein, humanASCL1GenitourinaryHigh-grade neuroendocrine carcinomaPPP1R12ARhabdomyosarcomaSarcomatoid carcinomaUrinary bladder

Identifiers

PMID30946934
PMCPMC8078053
OpenAlexW2933383115

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.